{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T14:09:03Z","timestamp":1794665343000,"version":"4.9.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.eururo.2025.03.019","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T15:29:04Z","timestamp":1748359744000},"page":"167-175","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Magnetic Resonance Imaging\u2013led Risk-adapted Active Surveillance for Prostate Cancer: Updated Results from a Large Cohort Study"],"prefix":"10.1016","volume":"88","author":[{"given":"Cameron","family":"Englman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Busola","family":"Adebusoye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Maffei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasilis","family":"Stavrinides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Bridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Kirkham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Dickinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doug","family":"Pendse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shonit","family":"Punwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navin","family":"Ramachandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun Wah","family":"So","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiman","family":"Haider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alistair","family":"Grey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clement","family":"Orczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Withington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Wilkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veeru","family":"Kasivisvanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Emberton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Mallett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Giganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline M.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2025.03.019_b0005","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer\u20142024 update. Part I: screening, diagnosis, and local treatment with curative intent","volume":"86","author":"Cornford","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.03.019_b0010","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/JU.0000000000002758","article-title":"Clinically localized prostate cancer: AUA\/ASTRO guideline, part II: principles of active surveillance, principles of surgery, and follow-up","volume":"208","author":"Eastham","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.03.019_b0015","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.1439","article-title":"Time trends and variation in the use of active surveillance for management of low-risk prostate cancer in the US","volume":"6","author":"Cooperberg","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.eururo.2025.03.019_b0020","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.eururo.2016.06.007","article-title":"A decade of active surveillance in the PRIAS study: an update and evaluation of the criteria used to recommend a switch to active treatment","volume":"70","author":"Bokhorst","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.03.019_b0025","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.eururo.2019.12.017","article-title":"Active surveillance of grade group 1 prostate cancer: long-term outcomes from a large prospective cohort","volume":"77","author":"Tosoian","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.03.019_b0030","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1001\/jama.2024.6695","article-title":"Long-term outcomes in patients using protocol-directed active surveillance for prostate cancer","volume":"331","author":"Newcomb","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2025.03.019_b0035","first-page":"e740","article-title":"Active surveillance for low-risk prostate cancer: time trends and variation in the AUA Quality (AQUA) Registry","volume":"207","author":"Cooperberg","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.03.019_b0040","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1001\/jamaoncol.2016.3600","article-title":"Uptake of active surveillance for very-low-risk prostate cancer in Sweden","volume":"3","author":"Loeb","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2025.03.019_b0045","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.28646","article-title":"Adoption of new risk stratification technologies within US hospital referral regions and association with prostate cancer management","volume":"4","author":"Leapman","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.eururo.2025.03.019_b0050","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.eururo.2015.06.012","article-title":"Compliance rates with the Prostate Cancer Research International Active Surveillance (PRIAS) protocol and disease reclassification in noncompliers","volume":"68","author":"Bokhorst","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.03.019_b0055","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/bju.13410","article-title":"Complications after prostate biopsies in men on active surveillance and its effects on receiving further biopsies in the Prostate cancer Research International: Active Surveillance (PRIAS) study","volume":"118","author":"Bokhorst","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2025.03.019_b0060","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.eururo.2013.05.049","article-title":"Systematic review of complications of prostate biopsy","volume":"64","author":"Loeb","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.03.019_b0065","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.eururo.2018.10.025","article-title":"Reasons for discontinuing active surveillance: assessment of 21 centres in 12 countries in the Movember GAP3 Consortium","volume":"75","author":"Van Hemelrijck","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.03.019_b0070","doi-asserted-by":"crossref","first-page":"629","DOI":"10.3390\/jpm13040629","article-title":"Active surveillance for prostate cancer: past, current, and future trends","volume":"13","author":"de Vos","year":"2023","journal-title":"J Pers Med"},{"key":"10.1016\/j.eururo.2025.03.019_b0075","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.rcl.2023.06.009","article-title":"Active surveillance for prostate cancer: expanding the role of MR imaging and the use of PRECISE criteria","volume":"62","author":"Englman","year":"2024","journal-title":"Radiol Clin North Am"},{"key":"10.1016\/j.eururo.2025.03.019_b0080","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/s41585-022-00587-0","article-title":"The current role of MRI for guiding active surveillance in prostate cancer","volume":"19","author":"Ploussard","year":"2022","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.eururo.2025.03.019_b0085","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.eururo.2020.03.035","article-title":"Five-year outcomes of magnetic resonance imaging-based active surveillance for prostate cancer: a large cohort study","volume":"78","author":"Stavrinides","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.03.019_b0090","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1007\/s00330-020-07256-z","article-title":"Natural history of prostate cancer on active surveillance: stratification by MRI using the PRECISE recommendations in a UK cohort","volume":"31","author":"Giganti","year":"2021","journal-title":"Eur Radiol"},{"key":"10.1016\/j.eururo.2025.03.019_b0095","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41391-018-0058-5","article-title":"The natural history of prostate cancer on MRI: lessons from an active surveillance cohort","volume":"21","author":"Giganti","year":"2018","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2025.03.019_b0100","unstructured":"NICE. Guideline for prostate cancer: diagnosis and management. https:\/\/www.nice.org.uk\/guidance\/ng131\/chapter\/Recommendations#localised-and-locally-advanced-prostate-cancer."},{"key":"10.1016\/j.eururo.2025.03.019_b0105","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.eururo.2016.06.011","article-title":"Reporting magnetic resonance imaging in men on active surveillance for prostate cancer: the PRECISE recommendations\u2014a report of a European School of Oncology Task Force","volume":"71","author":"Moore","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.03.019_b0110","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.eururo.2024.03.014","article-title":"PRECISE version 2: updated recommendations for reporting prostate magnetic resonance imaging in patients on active surveillance for prostate cancer","volume":"86","author":"Englman","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.03.019_b0115","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"Von Elm","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2025.03.019_b0120","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0022-5347(05)65271-8","article-title":"Expectant management of nonpalpable prostate cancer with curative intent: preliminary results","volume":"167","author":"Carter","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.03.019_b0125","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1097\/01.ju.0000118224.54949.78","article-title":"An analysis of men with clinically localized prostate cancer who deferred definitive therapy","volume":"171","author":"Patel","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.03.019_b0130","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0022-5347(05)65174-9","article-title":"Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and\/or clinical progression","volume":"167","author":"Choo","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.03.019_b0135","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.eururo.2021.05.001","article-title":"Reliability of serial prostate magnetic resonance imaging to detect prostate cancer progression during active surveillance: a systematic review and meta-analysis","volume":"80","author":"Rajwa","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.03.019_b0140","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.euo.2020.09.002","article-title":"Can the use of serial multiparametric magnetic resonance imaging during active surveillance of prostate cancer avoid the need for prostate biopsies?\u2014A systematic diagnostic test accuracy review","volume":"4","author":"Hettiarachchi","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2025.03.019_b0145","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/bju.14513","article-title":"Four\u2010year outcomes from a multiparametric magnetic resonance imaging (MRI)\u2010based active surveillance programme: PSA dynamics and serial MRI scans allow omission of protocol biopsies","volume":"123","author":"Gallagher","year":"2019","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2025.03.019_b0150","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.euo.2022.07.004","article-title":"Active surveillance for intermediate-risk prostate cancer: a systematic review, meta-analysis, and metaregression","volume":"5","author":"Baboudjian","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2025.03.019_b0155","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1002\/cncr.23502","article-title":"Active surveillance for the management of prostate cancer in a contemporary cohort","volume":"112","author":"Dall'Era","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2025.03.019_b0160","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.urology.2009.05.050","article-title":"Canary Prostate Active Surveillance Study: design of a multi-institutional active surveillance cohort and biorepository","volume":"75","author":"Newcomb","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2025.03.019_b0165","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/j.eururo.2007.05.011","article-title":"Prospective validation of active surveillance in prostate cancer: the PRIAS study","volume":"52","author":"Van den Bergh","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.03.019_b0170","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/bco2.351","article-title":"\u201cIt just makes sense to me\u201d: a qualitative study exploring patient decision-making and experiences with prostate MRI during prostate cancer active surveillance","volume":"5","author":"Sutherland","year":"2024","journal-title":"BJUI Compass"},{"key":"10.1016\/j.eururo.2025.03.019_b0175","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1097\/JU.0000000000000693","article-title":"The Magnetic Resonance Imaging in Active Surveillance (MRIAS) trial: use of baseline multiparametric magnetic resonance imaging and saturation biopsy to reduce the frequency of surveillance prostate biopsies","volume":"203","author":"Amin","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2025.03.019_b0180","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.euros.2022.12.013","article-title":"Prospective implementation and early outcomes of a risk-stratified prostate cancer active surveillance follow-up protocol","volume":"49","author":"Thankapannair","year":"2023","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.eururo.2025.03.019_b0185","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.euros.2023.10.005","article-title":"Magnetic resonance imaging-guided active surveillance without annual rebiopsy in patients with grade group 1 or 2 prostate cancer: the prospective PROMM-AS study","volume":"59","author":"Valentin","year":"2024","journal-title":"Eur Urol Open Sci"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283825001927?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283825001927?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T12:39:39Z","timestamp":1753274379000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283825001927"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0302283825001927"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2025.03.019","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Magnetic Resonance Imaging\u2013led Risk-adapted Active Surveillance for Prostate Cancer: Updated Results from a Large Cohort Study","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2025.03.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}